-
1
-
-
0030272248
-
Interleukin 2 and its receptors: Recent advances and new immunological functions
-
Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17:481-6.
-
(1996)
Immunol Today
, vol.17
, pp. 481-486
-
-
Theze, J.1
Alzari, P.M.2
Bertoglio, J.3
-
2
-
-
0343464573
-
Inhibition of non-hemopoietic cancer cell growth by interleukin-4 and related cytokines
-
Dalgleish AG, Browning M, eds. Cambridge: University Press
-
Hoon DSB, Morisaki T, Essner R. Inhibition of non-hemopoietic cancer cell growth by interleukin-4 and related cytokines. In: Dalgleish AG, Browning M, eds. Tumor immunology. Immunotherapy and cancer vaccines. Cambridge: University Press; 1996. p. 219-40.
-
(1996)
Tumor Immunology. Immunotherapy and Cancer Vaccines
, pp. 219-240
-
-
Hoon, D.S.B.1
Morisaki, T.2
Essner, R.3
-
3
-
-
0028304484
-
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
-
Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12:1475-83.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1475-1483
-
-
Schwartzentruber, D.J.1
Hom, S.S.2
Dadmarz, R.3
-
4
-
-
0027980190
-
Interleukin-2: Solid-tumor therapy
-
Oppenheimer MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 1994; 51:154-69.
-
(1994)
Oncology
, vol.51
, pp. 154-169
-
-
Oppenheimer, M.H.1
Lotze, M.T.2
-
5
-
-
0026485322
-
Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ
-
Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992; 52: 5963-70.
-
(1992)
Cancer Res
, vol.52
, pp. 5963-5970
-
-
Weidmann, E.1
Sacchi, M.2
Plaisance, S.3
-
6
-
-
0031914321
-
Cancer-associated muc1 mucin inhibits human t-cell proliferation, which is reversible by il-2
-
Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4:43-9.
-
(1998)
Nat Med
, vol.4
, pp. 43-49
-
-
Agrawal, B.1
Krantz, M.J.2
Reddish, M.A.3
Longenecker, B.M.4
-
7
-
-
0026348767
-
Cytokine regulation of eosinophil function
-
Weller PF. Cytokine regulation of eosinophil function. Clin Immunol Immunop 1992; 62:S55-9.
-
(1992)
Clin Immunol Immunop
, vol.62
-
-
Weller, P.F.1
-
8
-
-
0023115642
-
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
-
Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
-
(1987)
N Engl J Med
, vol.316
, pp. 889-897
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Muul, L.M.3
-
9
-
-
0023123517
-
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
-
West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905.
-
(1987)
N Engl J Med
, vol.316
, pp. 898-905
-
-
West, W.H.1
Tauer, K.W.2
Yannelli, J.R.3
-
10
-
-
0025330178
-
Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies
-
Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 1990; 335:1509-12.
-
(1990)
Lancet
, vol.335
, pp. 1509-1512
-
-
Atzpodien, J.1
Körfer, A.2
Franks, C.R.3
Poliwoda, H.4
Kirchner, H.5
-
11
-
-
0030798858
-
Effectiveness of very low doses of immunotherapy in advanced renal cell cancer
-
Buzio C, De Palma G, Passalacqua R, et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 1997; 76:541-4.
-
(1997)
Br J Cancer
, vol.76
, pp. 541-544
-
-
Buzio, C.1
De Palma, G.2
Passalacqua, R.3
-
12
-
-
0031572573
-
Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin-2 immunotherapy
-
Porta C, Moroni M, Bobbio-Pallavicini E, Tinelli C, Regazzi-Bonora M. Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin-2 immunotherapy. J Natl Cancer Inst 1997; 89:1545.
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 1545
-
-
Porta, C.1
Moroni, M.2
Bobbio-Pallavicini, E.3
Tinelli, C.4
Regazzi-Bonora, M.5
-
13
-
-
0026663801
-
Tumor-associated eosinophilia in interleukin-2-treated patients: Evidence of toxic eosinophil degranulation on bladder cancer cells
-
Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin 1992; 118:463-7.
-
(1992)
J Cancer Res Clin
, vol.118
, pp. 463-467
-
-
Huland, E.1
Huland, H.2
-
14
-
-
0027298415
-
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5
-
Rivoltini L, Viggiano V, Spinazzè, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993; 54:8-15.
-
(1993)
Int J Cancer
, vol.54
, pp. 8-15
-
-
Rivoltini, L.1
Viggiano, V.2
-
15
-
-
0031574104
-
Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: A preliminary report
-
Moroni M, Porta C, Gritti D, et al. Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: a preliminary report. Ann NY Acad Sci 1997; 832:295-303.
-
(1997)
Ann NY Acad Sci
, vol.832
, pp. 295-303
-
-
Moroni, M.1
Porta, C.2
Gritti, D.3
-
16
-
-
0026786510
-
Correlation ofeosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C
-
Arinaga S, Karimine N, Takamuku K, et al. Correlation ofeosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immun 1992; 35:246-50.
-
(1992)
Cancer Immunol Immun
, vol.35
, pp. 246-250
-
-
Arinaga, S.1
Karimine, N.2
Takamuku, K.3
-
17
-
-
0020349687
-
Influence of macrophage activation on the synthesis of complement components C2, C3, C4
-
Hartung HP, Zanker B, Bitter-Suermann D. Influence of macrophage activation on the synthesis of complement components C2, C3, C4. Adv Exp Med Biol 1982; 155:525-9.
-
(1982)
Adv Exp Med Biol
, vol.155
, pp. 525-529
-
-
Hartung, H.P.1
Zanker, B.2
Bitter-Suermann, D.3
-
18
-
-
0028913615
-
Benign idiopathic hypereosinophilia: A feeble masquerader or a smouldering form of the hypereosinophilic syndrome?
-
Confalonieri M, Tacconi F, De Amici M, et al. Benign idiopathic hypereosinophilia: a feeble masquerader or a smouldering form of the hypereosinophilic syndrome? Haematologica 1995; 80:50-3.
-
(1995)
Haematologica
, vol.80
, pp. 50-53
-
-
Confalonieri, M.1
Tacconi, F.2
De Amici, M.3
-
19
-
-
0003486931
-
-
Offset publication 48. Geneva, World Health Organization
-
World Health Organization. WHO Handbook for reporting results of cancer treatment. Offset publication 48. Geneva, World Health Organization, 1979.
-
(1979)
Who Handbook for Reporting Results of Cancer Treatment
-
-
-
21
-
-
0026442546
-
Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer
-
Fiorentino B, Di Stefano P, Giuliani C, et al. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. Br J Cancer 1992; 66:981-3.
-
(1992)
Br J Cancer
, vol.66
, pp. 981-983
-
-
Fiorentino, B.1
Di Stefano, P.2
Giuliani, C.3
-
22
-
-
0026500134
-
Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: Clinical results and immunological effects
-
Hermann GG, Geertsen PF, von der Maase H, et al. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res 1992; 52:726-33.
-
(1992)
Cancer Res
, vol.52
, pp. 726-733
-
-
Hermann, G.G.1
Geertsen, P.F.2
Von Der Maase, H.3
-
23
-
-
0027399765
-
Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo
-
Schneekloth H, Korfer A, Hadam M, et al. Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 1993; 89:13-21.
-
(1993)
Acta Haematol
, vol.89
, pp. 13-21
-
-
Schneekloth, H.1
Korfer, A.2
Hadam, M.3
-
24
-
-
0027450783
-
A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans
-
Schiller JH, Hank J, Storer B, et al. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans. Cancer Res 1993; 53:1286-92.
-
(1993)
Cancer Res
, vol.53
, pp. 1286-1292
-
-
Schiller, J.H.1
Hank, J.2
Storer, B.3
-
25
-
-
0029595269
-
High-dose continuous venous infusion of interleukin-2: Influence of dose and infusion rate on tumoricidal function and lymphocyte subsets
-
Mertens WC, Banerjee D, al-Mutter N, Stitt L, Bramwell VH, Lala PK. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets. Cancer Immunol Immun 1995; 41:271-9.
-
(1995)
Cancer Immunol Immun
, vol.41
, pp. 271-279
-
-
Mertens, W.C.1
Banerjee, D.2
Al-Mutter, N.3
Stitt, L.4
Bramwell, V.H.5
Lala, P.K.6
-
29
-
-
0022474118
-
Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex
-
Siu H, Vitetta ES, May RD, Uhr JW. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol 1986; 137:1376-82.
-
(1986)
J Immunol
, vol.137
, pp. 1376-1382
-
-
Siu, H.1
Vitetta, E.S.2
May, R.D.3
Uhr, J.W.4
-
30
-
-
0020646433
-
Suppression and elimination of BCL1 leukemia byallogeneic bone marrow transplantation
-
Weiss L, Morecki S, Vitetta ES, Slavin S. Suppression and elimination of BCL1 leukemia byallogeneic bone marrow transplantation. J Immunol 1983; 130:2452-5.
-
(1983)
J Immunol
, vol.130
, pp. 2452-2455
-
-
Weiss, L.1
Morecki, S.2
Vitetta, E.S.3
Slavin, S.4
-
31
-
-
0026425697
-
Cancer dormancy: Studies of the murine BCL-1 lymphoma
-
Uhr JW, Tucker T, May RD, Siu H, Vitetta ES. Cancer dormancy: studies of the murine BCL-1 lymphoma. Cancer Res 1991; 51:5045s-5053s.
-
(1991)
Cancer Res
, vol.51
-
-
Uhr, J.W.1
Tucker, T.2
May, R.D.3
Siu, H.4
Vitetta, E.S.5
-
32
-
-
0028018095
-
Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection
-
Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994; 91:7430-4.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 7430-7434
-
-
Khazaie, K.1
Prifti, S.2
Beckhove, P.3
-
33
-
-
0342594637
-
The immunosurveillance of cancer: Specific and nonspecific mechanisms
-
Dalgleish AG, Browning M, eds. Cambridge: University Press
-
Vile RG, Chong H, Dorudi S. The immunosurveillance of cancer: specific and nonspecific mechanisms. In: Dalgleish AG, Browning M, eds. Tumor immunology. Immunotherapy and cancer vaccines. Cambridge: University Press; 1996. p. 7-38.
-
(1996)
Tumor Immunology. Immunotherapy and Cancer Vaccines
, pp. 7-38
-
-
Vile, R.G.1
Chong, H.2
Dorudi, S.3
-
34
-
-
0025916290
-
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
-
Lissoni P, Tisi E, Brivio F, et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 1991; 27:1014-6.
-
(1991)
Eur J Cancer
, vol.27
, pp. 1014-1016
-
-
Lissoni, P.1
Tisi, E.2
Brivio, F.3
-
35
-
-
0027270598
-
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results
-
Lissoni P, Barni S, Rovelli F, et al. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer 1993; 29A: 185-9.
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 185-189
-
-
Lissoni, P.1
Barni, S.2
Rovelli, F.3
-
36
-
-
0026689558
-
The origin and function of tumor-associated macrophages
-
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13:265-70.
-
(1992)
Immunol Today
, vol.13
, pp. 265-270
-
-
Mantovani, A.1
Bottazzi, B.2
Colotta, F.3
Sozzani, S.4
Ruco, L.5
-
37
-
-
0027494385
-
Action of natural killer cells and macrophages in cancer
-
Klein E, Mantovani A. Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 1993; 5: 714-8.
-
(1993)
Curr Opin Immunol
, vol.5
, pp. 714-718
-
-
Klein, E.1
Mantovani, A.2
-
38
-
-
0028132648
-
Alveolar macrophage inhibition of lung-associated NK activity: Involvement of prostaglandins and transforming growth factor-beta 1
-
Lauzon W, Lemaire I. Alveolar macrophage inhibition of lung-associated NK activity: involvement of prostaglandins and transforming growth factor-beta 1. Exp Lung Res 1994; 20:331-49.
-
(1994)
Exp Lung Res
, vol.20
, pp. 331-349
-
-
Lauzon, W.1
Lemaire, I.2
-
39
-
-
0029835231
-
The role of tumor necrosis factor (TNF) family members in IL-2 toxicity and tumor regression
-
Mier J, Lawrence D, Unrau M, Atkins M. The role of tumor necrosis factor (TNF) family members in IL-2 toxicity and tumor regression. Int J Immunopathol 1996; 2:39-42.
-
(1996)
Int J Immunopathol
, vol.2
, pp. 39-42
-
-
Mier, J.1
Lawrence, D.2
Unrau, M.3
Atkins, M.4
-
40
-
-
0029840585
-
Fas ligand and immune evasion
-
Nagata S. Fas ligand and immune evasion. Nat Med 1996; 2:1306-7.
-
(1996)
Nat Med
, vol.2
, pp. 1306-1307
-
-
Nagata, S.1
-
41
-
-
0026754550
-
Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer
-
Flamm J. Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer. Urology 1992; 40:180-5.
-
(1992)
Urology
, vol.40
, pp. 180-185
-
-
Flamm, J.1
-
42
-
-
0027970322
-
Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx
-
Thompson AC, Bradley PJ, Griffin NR. Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx. Am J Surg 1994; 168:469-71.
-
(1994)
Am J Surg
, vol.168
, pp. 469-471
-
-
Thompson, A.C.1
Bradley, P.J.2
Griffin, N.R.3
-
43
-
-
0030024150
-
Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma
-
Leighton SE, Teo JG, Leung SF, Cheung AY, Lee JC, van-Hasselt CA. Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer 1996; 77:436-40.
-
(1996)
Cancer
, vol.77
, pp. 436-440
-
-
Leighton, S.E.1
Teo, J.G.2
Leung, S.F.3
Cheung, A.Y.4
Lee, J.C.5
Van-Hasselt, C.A.6
-
44
-
-
0030837554
-
Eosinophils and human cancer
-
Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997; 12:807-12.
-
(1997)
Histol Histopathol
, vol.12
, pp. 807-812
-
-
Samoszuk, M.1
-
45
-
-
0030765161
-
The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer
-
Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 1997; 98:312-4.
-
(1997)
Br J Haematol
, vol.98
, pp. 312-314
-
-
Trulson, A.1
Nilsson, S.2
Venge, P.3
-
46
-
-
0031864807
-
Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer
-
Porta C, Moroni M, De Amici M. Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer. Br J Haematol 1998; 100:607-9.
-
(1998)
Br J Haematol
, vol.100
, pp. 607-609
-
-
Porta, C.1
Moroni, M.2
De Amici, M.3
|